The 3 top equipments available
Leveraging its patented MSP methylation technology, MDxHealth is developing and commercializing a robust pipeline of prognostic and predictive molecular diagnostic products for multiple cancer types. Through its network of clinical collaborations, the company is commercializing these tests to improve patient outcomes and lower healthcare costs.
For each cancer type, the company will offer a combination of different assays:
ConfirmMDx – Our “Confirm” products will serve as an aid for physicians to assess DNA methylation status associated with presence or absence of cancer.
InformMDx – Our “Inform” products will provide prognostic assessment to distinguish between aggressive and non-aggressive tumors.
PredictMDx – Our “Predict” products will provide predictive information to indicate which drug or treatment regimen is likely to be most effective for the individual patient.
Know-how, expertise available
MDxHealth’s Clinical Molecular Diagnostics (ClinicalMDx) business is focused on providing physicians with innovative and meaningful assays that aid in the identification and treatment of their cancer patients.
MDxHealth’s ClinicalMDx strategy is to develop and commercialize advanced epigenetic tests through its U.S.-based CLIA-accredited, CAP-certified laboratory facility. The ClinicalMDx business also includes epigenetic products commercialized by our partners and third party sublicensees.
MDxHealth’s ClinicalMDx portfolio is divided into three primary categories including diagnostic, prognostic and predictive molecular diagnostic tests for multiple cancer types. These tests are designed to address current diagnostic dilemmas faced by clinicians and will deliver actionable results to help improve patient management decisions.
This could give a more general overview of what MDxHealth can offer. Please let me know if you think appropriate to add the information or you if you would like to add a different one. Then I will publish the profile and give you the access codes.
Possibilities of partnership
Company is very experienced in the development and succesfull commercialization of these products. In partricular developing products under design control (FDA regulation). The company is very experienced in the building out new laboratory infrastructure and in a very short time frame (6-9 months from start to finish)
Currently the company has established a partnership with an other Belgium based histopathology lab and togethr with the University of Gent MDxHealth is the partner on the Center of Pharmco(Epi)Genomics in Gent. Company has also very strong scientific collaborations with the pathology department of pathology at the VUMC in Amsterdam, IPG in Belgium, and University of Maastrcht. Outside Europe the company has research colaborations in place with the Johns Hopkins University in Baltimore, Harvard medical School, UCLA CA and may other cancer centers in the USA.
JHU University ->Lung cancer
Harvard medical ->School Prostate cancer
VUMC Amsterdam -> Colon cancer
Uni of Edinburgh -> Prostate and Kidney cancer
Uni of Lausanne -> Brain cancer (Prof Monica Hegi)
Terms of availability for SMEs
To establish a regional central state of the art molecular pathology service laboratory (project name HistoHealth). This central laboratory will provide innovative molecular diagnostic services as well as the traditional histopathology service, including imaging, quantification and tumor profiling to all the hospitals in the area. The big advantage of this would be that the latest new available oncology assays can be offered to the physicians to provide better treatment for their patients. With a focus on precision medicine within oncology many of the cancer specific diagnostic assays are expensive to be implemented in each local pathology laboratory. Centralizing these type of services will be extremely cost efficient.
This newly established molecular pathology lab will also provide high level clinical trial services for pharmaceutical companies.
- A central molecular pathology laboratory is the only efficient options for the future
- Histohealth will become a knowledge center
- Histohealth will become a roll model within the Netherlands
- Histohealth will generate new high level jobs for the region
- Histohealth will contribute to cost savings within healthcare.
Quality labels and accreditations
Histohealth needs to be in compliance with the respective laboratory ISO certifications in order to deliver top level services to their clients. The Histohealth staff need to have necessary qualifications in order to operate a clinical pathology laboratory. For pharmaceutical services the company needs to be in compliance with CLIA and FDA regulations.
MDxhealth has obtained the following quality labels
New York State lisence
5 additional state licensees for the US market
MDxhealth clinical diagnostic activities are focussing on the US and EU market. Regarding our pharmacodiagnostic activities we are operating on a global level.
Training and Staff possibilities
Training and Staff exchange terms and conditions
For this application we are targeting the regional market